Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who had undergone cataract extraction with intraocular lens implantation
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OTX-DP | Experimental | OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use |
|
| PV | Placebo Comparator | PV (placebo drug delivery vehicle) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexamethasone | Drug |
| ||
| Placebo Vehicle |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With an Absence of Anterior Chamber Inflammation | Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14 | Day 14 |
| Number of Participants With an Absence of Ocular Pain | Absence of pain (i.e., score of '0') in the study eye at Day 8 | Day 8 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Dexamethasone Punctum Plug | Drug treatment |
| FG001 | Placebo Vehicle Punctum Plug | No drug treatment |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | OTX-DP (Dexamethasone Punctum Plug) | Resorbable hydrogel drug delivery vehicle containing dexamethasone Dexamethasone |
| BG001 | PVPP (Placebo Punctum Plug) | Resorbable hydrogel drug delivery vehicle containing no drug Punctum Plug |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With an Absence of Anterior Chamber Inflammation | Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14 | Posted | Number | participants | Day 14 |
|
|
| ||||||||||||||||||||||||||||||
| Primary | Number of Participants With an Absence of Ocular Pain | Absence of pain (i.e., score of '0') in the study eye at Day 8 | Posted | Number | participants | Day 8 |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dexamethasone Punctum Plug | Drug treatment | 0 | 160 | 0 | 160 | ||
| EG001 | Placebo Vehicle Punctum Plug | No drug treatment | 1 | 80 | 0 | 80 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| mental disorder | Psychiatric disorders |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jamie L. Metzinger, Medical Affairs | Ocular Therapeutix | 781-357-4000 | jmetzinger@ocutx.com |
| ID | Term |
|---|---|
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
Not provided
Not provided
| >=65 years |
|
| Male |
|
|